A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, and multicenter phase Ⅱ study designed to evaluate the
efficacy and safety of F520 (PD-1) combined with F007(rituximab biosimilar) in patients with
Relapsed/Refractory diffuse large B-cell lymphoma. About 62 patients with relapsed/refractory
DLBCL plan to be enrolled in about 8 study sites of the study.
Primary objective:
The purpose is to evaluate the objective response rate of F520 combined with F007 in
Relapsed/Refractory diffuse large B-cell lymphoma.
Secondary objective:
The purpose is to compare the safety of F520 combined with F007 in Relapsed/Refractory
diffuse large B-cell lymphoma.